The company and its board of directors ensure that the content of this announcement is true, accurate, complete, and free of false records or misleading statements.
Beijing Ruimaite Medical Technology Co., Ltd. (hereinafter referred to as "the Company") held its 2026 annual general meeting on April 27, 2026, and approved the buyback plan for the Company's shares. The buyback amount shall not exceed RMB 12 million (inclusive) and shall not exceed RMB 6 million (inclusive) for the total number of shares to be repurchased. The repurchase price shall not exceed RMB 73.88 per share (inclusive). The implementation of the buyback plan is subject to the approval of the shareholders' meeting, and the Company shall not exceed 12 months for the buyback.